Project information

The John Goldman Fellowship for Future Science

Prof John Goldman, Leuka founder was a towering figure in the world of haematology who developed ground breaking treatments for leukaemia patients, while also nurturing the talents of future scientists. In this memory, we are hoping to fund research from scientific leaders of tomorrow.

2 years

Charity information: Leuka

Leuka logo
  • Need

    Need

    We know that the prognosis of childhood leukaemia, which is the main form of cancer amongst this age group is poor. The Chromosomal abnormalities in children involving the MLL gene represents the most aggressive and drug resistant form of leukaemia but we do not know why it does not respond to chemotherapy. Most commonly resistance to this is due to the manipulation of DNA damage repair which is usually rectified by phosphate PP2A and we will look at its role on drug resistance of MLL leukaemia

    Solution

    We want to fund one of our Fellows who will conduct dedicated research by using in vitro and in vivo models, the role of PP2A on drug resistance to MLL Leukaemia to introduce targeted personalised treatments, taking into account the DNA mutations.

  • Aims

    Aim 1

    To use previously untapped investigations to aid the prognosis of childhood leukaemia

    Activities

    » To fund innovative investigations of the highest scientific quality to help patient outcomes. Fellows will use previously unexplored research methods

    We will look at the restoration of phosphatase PP2A, and why it is inactive, tested in a cell models. The results will inform whether PP2A reactivation with drugs can save lives


    Aim 2

    To fund areas of research which have previously been unexplored while nurturing future scientists

    Activities

    » With funding we will support exceptional future scientists who find it hard to get support as money is only readily available for established research

    We aim to fund promising researchers over a two year period, establishing a monitoring framework requiring milestone impact reporting.


  • Impact

    Impact

    This research project will consider whether new drugs can react to the non responsive PP2A and therefore provide a better prognosis for children with leukaemia. This 2 year project will lay the solid foundations providing sound data for clinical trials and exploring cell cycle checkpoint suppression and DNA damage repair to minimise chemotherapy resistance of MLL leukaemia - coupled with the mentoring offered as part of the fund, we should see a marked transformation in the treatments provided

    Risk

    The risks are that the Fellow decides to terminate the research. We have put in place firm plans with terms and conditions signed in addition to ensuring that each individual is Sponsored by a leader in the field. The research also could take longer than expected and again through our careful monitoring and peer reviews, we will be able to mitigate against this.

    Reporting

    we will provide detailed impact reports meeting an agreed timeframe. We also ask that they publish their research findings in accordance with the terms and conditions of accepting any funding

  • Budget

    Budget - Project Cost: £11,000

    Loading graph....
      Amount Heading Description
      £7,500 research consumables anti bodies, kits for extracting protein, cell dishes
      £2,000 DNA sequencing technology that is used to determine the order of the four bases—adenine, guanine, cytosine, and thy
      £1,500 Anti bodies A cocktail of anti bodies to detect a blood stem cell
  • Background

    Location

    The research will be undertaken at the University of East London in collaboration with Barts Cancer Research Institute Queen Mary University of London.

    Beneficiaries

    Ultimately the project will benefit children with MLL leukaemia to ensure a more positive prognosis.

  • Why Us?

    Why Us?

    As the leading leukaemia research charity, we are determined to find the root cause of the many variations of leukaemia, the best treatments as soon as possible and ultimately a cure. unlike other organisations we are solely devoted to leukaemia research and with a strong medical advisory board all applications are subject to a vigorous scientific panel review. Again, we will support novel, clearly defined projects which re translational delivering positive patient outcomes

    Read more about the Charity running this project.

    People

    Dr Dawn Farrar

    Dr Farrar is our Research Manager who initially reviews applications to put forward to our scientific panel. She is the conduit for all research.